MRK
Merck & Co., Inc. · Healthcare
120.89
0.02%(+0.02)
Prev. Close120.91
0.02%(+0.02)
Pre-marketLast Updated: — ET
52W L: $73.3152W H: $125.14
$120.41
CHG+6.30 (+5.52%)
H$122.12
L$112.49
VOL112M
MRK (1h)
Merck & Co., Inc. · Healthcare
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Leo Wealth LLC increased its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 29.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,848 shares of the company's stock after buying an additional 6,078 shares during the quarter. Leo Wealth
Savvy Advisors Inc. grew its position in shares of Merck and Co., Inc. (NYSE: MRK) by 50.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,567 shares of the company's stock after buying an additional 8,627 shares during
The drugmaker's stock recently got a shot in the arm on the news of it acquiring Terns Pharmaceutical—a move that will not only bolster its cancer treatment pipeline but also reinforce Merck's role as a top-tier serial acquirer.
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.26%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.
Analyst IMS Investment Management Services Ltd. boosted its stake in Merck and Co., Inc. (NYSE: MRK) by 301.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 10,298 shares of the company's stock after purchasing an additional 7,733 shares during the period. Analyst IMS Investment Management
Seidman Christine E
director
67.545 SH @ $0.00
2026-03-31
GLOCER THOMAS H
director
405.271 SH @ $0.00
2026-03-31
Coe Mary Ellen
director
249.397 SH @ $0.00
2026-03-31
Foard Brian
officer
0 SH @ $0.00
2026-03-02
Guindo Chirfi
officer: Chief Marketing Officer
10,000 SH @ $121.46
2026-02-12
Li Dean Y
officer: Executive VP & President, MRL
10,235 SH @ $117.52
2026-02-10
Guindo Chirfi
officer: Chief Marketing Officer
10,000 SH @ $118.41
2026-02-09
Zachary Jennifer
officer: EVP, General Counsel
56,792 SH @ $119.15
2026-02-09